Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones
Featured News & Press Releases
Apr 08, 2022: Phio Pharmaceuticals presents positive new data on PH-894 demonstrating antitumor efficacy in model of PD-1 refractory disease at the AACR Annual Meeting 2022
Mar 30, 2022: VYNE Reports positive preclinical data for intra-articular injection of pan-BET inhibitor, VYN201, in an in vivo model of rheumatoid arthritis
Mar 17, 2022: Apabetalone’s Positive Impact on Pulmory Arterial Hypertension Published in the American Jourl of Respiratory and Critical Care Medicine
Mar 08, 2022: Phio Pharmaceuticals announces upcoming presentation of PH-894 data at the AACR Annual Meeting 2022
Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo
Feb 22, 2022: Zenith Epigenetics announces dosing of first cancer patient with a combition of ZEN-3694 + Bristol Myers Squibb’s immune checkpoint inhibitor OPDIVO
Feb 18, 2022: Resverlogix expands Phase IIb apabetalone trial for Covid-19
Feb 15, 2022: Ranok Therapeutics to present at BMO Biopharma spotlight series on protein degraders and other Next Gen
Jan 24, 2022: Ranok Therapeutics announces U.S. FDA clearance to proceed with its first-in-human trial of RNK05047 in patients With advanced solid tumor cancers and lymphomas (CHAMP-1)
Jan 21, 2022: US FDA clears Nuvation Bio’s application for solid tumour therapy
Jan 19, 2022: Resverlogix starts Phase IIb oral Covid-19 drug trial
Jan 18, 2022: Resverlogix announces commencement of patient enrollment and dosing in a phase 2b trial for a promising Cadian-developed COVID-19 treatment
Dec 12, 2021: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Nov 04, 2021: MorphoSys to present MANIFEST data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
Nov 04, 2021: Lead BET inhibitor, VYN201, demonstrates improvement in reducing fibrotic tissue mass and overall skin repair outcomes in preclinical study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Products under Development by Companies, 2022 (Contd..9)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AbbVie Inc, 2022
Pipeline by Amgen Inc, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Bromodomain Pharmaceuticals Inc, 2022
Pipeline by C4 Therapeutics Inc, 2022
Pipeline by Checkpoint Therapeutics Inc, 2022
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Pipeline by Constellation Pharmaceuticals Inc, 2022
Pipeline by ConverGene LLC, 2022
Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Pipeline by Epigene Therapeutics Inc, 2022
Pipeline by Kainos Medicine Inc, 2022
Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2022
Pipeline by Nuvation Bio Inc, 2022
Pipeline by OHM Oncology, 2022
Pipeline by Phio Pharmaceuticals Corp, 2022
Pipeline by Plexium Inc, 2022
Pipeline by Plexxikon Inc, 2022
Pipeline by Ranok Therapeutics Co Ltd, 2022
Pipeline by Red Glead Discovery AB, 2022
Pipeline by Resverlogix Corp, 2022
Pipeline by Roivant Sciences Ltd, 2022
Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022
Pipeline by Sierra Oncology Inc, 2022
Pipeline by SignalRx Pharmaceuticals Inc, 2022
Pipeline by VYNE Therapeutics Inc, 2022
Pipeline by Zenith Epigenetics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Dormant Products, 2022 (Contd..4)
Dormant Products, 2022 (Contd..5)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)